Modulation of Dextran Sulphate Sodium-Induced Colonic Inflammation by Local Supplementation of Leptin

Corinne Nazaret¹, Sandra Guilmeau¹, Yassine Sakar¹, Francine Walker¹, Robert Ducroc¹, Thomas Aparicio¹, Thérèse Lehy¹, Christine Linard² and André Bado*,¹

¹INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon; UFR de Médecine Paris 7 - Denis Diderot; IFR02 Claude Bernard, 16 rue Henri Huchard, BP 416, F-75018, Paris, France
²Institut de Radioprotection et de Sûreté Nucléaire, Direction de la Radioprotection de l’Homme, Laboratoire de Radiopathologie 92262 Fontenay-aux roses Cedex, France

Abstract: Background & Aims: Leptin is overproduced in gastrointestinal mucosa during inflammatory processes, suggesting that mucosal cells represent sources of secreted leptin active in the lumen. The effects of leptin, acting apically from colonic epithelial cells, were analysed on dextran sulphate sodium-induced colonic inflammation in rats.

Methods: We determined the effects of intracolonic leptin on the phosphorylation of STAT3, MAPkinase and on colon mucosa-derived inflammation-related genes (IL-8, IL-1β, TNFα, COX-2). Colitis was induced by administering dextran sodium sulphate. The effects of intracolonic leptin on DSS colitis was evaluated based on disease symptoms, cytokine expression and PPAR expression.

Results: In vivo, intracolonic leptin rapidly stimulated STAT-3 and p42-MAPK phosphorylation. We also detected a 3-fold increase in COX-2 induction, and a dose-dependent increase in mucosal PGE₂ content (EC₅₀ 0.89 nM). Intracolonic leptin reduced the severity of DSS-induced colitis, whereas intraperitoneal leptin exacerbated colitis. Intracolonic leptin decreased DSS-induced inflammatory IL-8 (−75%; P<0.01 vs DSS) and IL-1β (−60%; P<0.01 vs DSS); it also prevented a DSS-induced decrease in the levels of mucosa PPARα mRNA and increased the levels of PPARγ mRNA two-fold (P<0.01 vs DSS).

Conclusion: Leptin activates its apical receptor and this mechanism coupled to the activation of STAT-3 and MAPKinease signalling pathways may have a beneficial effect on the integrity of the epithelium upon mucosa injury. These data shed further light on the role of gastrointestinal luminaly acting leptin in the modulation of intestinal inflammation.

Keywords: Leptin, local action, dextran sulfate sodium, inflammation, colon, PPARs.

INTRODUCTION

Leptin, the ob gene product, initially described as a fat tissue-specific protein [1], is produced by other tissues and organs [2-5]. The biological actions of leptin are relayed by leptin receptors [6, 7] belonging to the class I cytokine receptor family. This family includes gp-120, the common signal transduction receptor for the IL-6-related family of cytokines. It is now generally accepted that leptin not only regulates food intake, but also participates in various biological processes. In this regard, extensive studies have implicated leptin in the regulation of both innate and adaptive immune responses [8, 9]. In particular, mice deficient for leptin (ob/ob) are resistant to colitis, and the treatment of these mice with circulating leptin confers susceptibility to inflammation [10]. This resistance to intestinal inflammation was also associated with reduced cytokine secretion, increased apoptosis of lamina propria lymphocytes (LPL), and was shown to largely involve T cell-mediated intestinal autoimmunity [11, 12]. In contrast to this pro-inflammatory role of systemic leptin, there is evidence for leptin anti-inflammatory role. Indeed, ob/ob mice were more likely to succumb after the administration of TNFα, an effect that is prevented by replacing leptin [13, 14]. Moreover, leptin protects against acute pancreatitis and is up-regulated in parallel during acute pancreatitis [15]. Furthermore, leptin protects against gastric mucosa injury induced by NSAIDs and alcohol [16, 17], and decreases the severity of acetic acid-induced colitis in rats [18].

By contrast, over-production of leptin has been demonstrated in gastric mucosa colonised with Helicobacter pylori [19, 20] in the pancreas during acute pancreatitis [15], and in the colon of patients with inflammatory bowel disease [21, 22]. Whether leptin up-regulation after tissue injury is causative in inflammatory responses or simply a marker of inflammation has not been formally proven. Thus, identifying the exact relationship between luminal leptin and intestinal inflammation remains to be determined. The aim of this study was to analyse the role of gut leptin acting apically from colonic epithelial cells (CEC) in the modulation of colonic inflammation using a DSS colitis model. We first determined the acute effects of intracolonic leptin on the activation of STAT3, MAPKinase signalling pathways, and...
on colon mucosa-derived IL-8, IL1β, TNFα and COX-2 genes in rats. We then evaluated the chronic effects of intracolonic leptin on DSS-induced colonic inflammation and analysed the possible mechanisms involved.

**MATERIALS AND METHODS**

**Animals.** Male Wistar rats weighing 220-250g (Elevage Janvier, France) were caged under standard laboratory conditions with tap water and regular rat chow provided ad libitum, in a 12 h/12 h light/dark cycle, at a temperature of 21-23°C. All animals were treated in accordance with the European Committee Standards concerning the care and use of laboratory animals and the experiments were conducted in accordance with the French regulations for animal experiments and with authorization Order No B75-18-02 received from the Ministry of Agriculture and Prefecture de Paris, France.

**Determination of leptin levels in plasma and luminal contents of colon.** 24-hour fasted rats were anesthetised, and blood samples were collected from the abdominal aorta. The samples were centrifuged and the plasma was stored at -20°C until leptin radioimmunoassays. The rats were then killed and the colon, from the after the caecum to rectum, was removed and luminal contents from the colon were collected. The collected contents were cleared by centrifugation (3000 rpm for 10 minutes), and the supernatants were stored at -20°C until analysis by leptin RIA (RIA kits Linco Research Inc., St Charles, Missouri). Size exclusion chromatography (SEC) was carried out using a Superdex 200 column (Pharmacia Biotech, Freiburg, Germany), as previously described [23].

**Effects of intracolonic leptin on TNF-α, IL-8, IL-1β and COX-2 expression.** 24-hour fasted rats were slightly anesthesitised with sodium pentobarbital (Sanofi, Libourne, France) and injected with vehicle PBS (control group) or 3 nM recombinant murine leptin (R&D systems), slowly administered through a catheter inserted rectally into the colon. The animals were killed 15, 30 and 60 min after injection for the western blot analysis of phosphoproteins. In a second set of experiments, 3 hours after the injection of vehicle or 3 nM leptin, the colon was removed. One part was fixed in Bouin solution, embedded in paraffin, sectioned at 4 μm, and stained with Alcian blue (AB, pH 2.5); this was followed by the periodic acid-Schiff reaction (PAS) and counterstaining with haematoxylin. The Blue alcian (AB)/Schiff Periodic acid (PAS) method yielded a blue colour if mostly acidic mucins were present and magenta if mostly neutral mucins were present. Another segment was rinsed with ice-cold 0.9% saline and the mucosa was scraped and immediately frozen for total RNA and protein extraction. The protein extracts were used for western blot analysis and for determining the PGE2 content by RIA using the [3H]-prostaglandin-E2 RIA Kit (Perkin Elmer, Zaventem, Belgium).

**Western blot analysis.** Unfrozen colon mucosa were homogenised at 4°C in lysis buffer containing 0.1% Triton X-100, 1 μg/ml phenylmethyl sulphonyl fluoride (PMSF), 50 mM Tris/HCl, 10 mM EDTA, phosphatase inhibitor cocktail, and 0.1% protease inhibitor cocktail (SIGMA, Saint Louis Mo, USA). Samples were centrifuged at 15,000 g for 30 min at 4°C and the supernatant protein concentrations were quantified using the BCA protein assay kit (Pierce, Rockford IL, USA). Proteins were resolved on 8-13% polyacrylamide gels, transferred onto nitrocellulose membranes and probed overnight with polyclonal rabbit antibody against STAT3, phospho-STAT3 (Tyr705), SOCS-3 from Novus Biologicals, Inc. (Littleton, CO, USA), ERK-1 from Santa Cruz Biotechnology (California, USA), each used at a dilution of 1:1000, and monoclonal mouse antibody phospho p44/p42 MAPK (Thr202/Tyr204) from Cell Signaling Technology, Inc. (Boston, MA). Monoclonal anti-β-actin (clone AC-74 Sigma, St Louis Mo USA) was used as a loading control at a 1:5000 dilution.

The membranes were incubated with two horseradish peroxidase-conjugated secondary antibodies: donkey anti-rabbit (Santa Cruz Biotechnology, CA) and goat anti-mouse (Sigma, UK), diluted 1:10,000. The immune complexes were detected by an enhanced chemiluminescence detection system (Pierce, Rockford, IL, USA).

**Induction of colitis with DSS.** Colitis was induced with 5% (w/v) DSS (ICN Biomedicals Inc.) for 7 days; this was followed by 5 days of water intake as described previously [24]. Rats receiving drinking water (control) and DSS were treated once a day with intraperitoneal saline (control) or 6 nmol/kg recombinant murine leptin, with intracolonic PBS (control) or 6 nM leptin. The rats were killed on day 12, and the entire colon (from the caecum to anus) was excised and colon length was measured. Each colon was opened and assessed for colitis. A distal colon segment was removed to determine the tissue-associated myeloperoxidase (MPO) activity. Another segment from the proximal and middle colon was removed, rinsed and the mucosa was scraped to isolate total RNA and protein.

**Clinical and histological assessment of colitis.** The body weight and clinical signs of colitis, such as appearance of diarrhoea and blood in the stools, were determined daily after the start of DSS. We determined the disease activity index (DAI) by applying a score system as previously described [25]. For histological analysis, segments of distal colon were fixed in Bouin solution, were processed by various techniques described above, and were examined by light microscopy. Two pathologists (FW and TL), blinded to the protocol, carried out the histological scoring using the scheme modified by Barbier et al. [26].

**MPO activity determination.** Tissue myeloperoxidase (MPO) activity was determined using the O-dianisidine hydrochloride method as previously described [27]. Protein concentrations of each sample were determined using the Bio-Rad protein assay (Bio-rad Laboratories, Richmond, CA).

**Quantitative real-time polymerase chain reaction (qRT-PCR).** Total RNA was extracted from colon mucosa samples with the RNAeasy kit (Qiagen). The mRNA levels of inflammation-related cytokines and PPARs, and of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) were measured by real-time polymerase chain reaction (RT-PCR), as previously described [28] with the primer sequences listed in Table I. We used the comparative ΔΔCT-method for the relative mRNA quantification of target genes, normalised to an endogenous reference (HPRT) and a relevant control equal to 2^{-ΔΔCT}.
Statistical analysis. The results are expressed as the mean ± SEM. Results were compared by one-way analysis of variance (ANOVA), followed by a Tukey-Kramer multiple comparisons test if significant results were obtained.

RESULTS

Leptin detection in colonic luminal contents. Leptin-immunoreactive (IR) protein was detected in the luminal contents from the colon (at levels two-fold lower than circulating leptin levels in non-fasted rats (Fig. 1A).

Intracolonic leptin phosphorylates STAT-3 and ERK proteins, and induces SOCS-3 protein production. We administered leptin directly into the colon lumen and investigated the activation of leptin-receptors coupled to STAT and MAPKinase pathways to test if luminal leptin had any biological effects on the colonic mucosa. Immunoblotting of extracts from colon mucosa treated for 30 min with intracolonic leptin (3nM) showed that STAT-3 and ERK phosphorylation were significantly increased (P<0.01). This leptin-induced phosphorylation was even more prominent for p42 MAPK. We observed an even greater degree of STAT3 phosphorylation together with a parallel decrease in p42 MAPK phosphorylation 60 mins after administration. Moreover, the protein levels of mucosa SOCS-3 protein, a negative regulator leptin-receptor signalling, were greater 60 min after the administration of IC leptin.

IL-1β, IL-8 and TNF-α mRNA levels showed no significant change three hours after the administration of 3nM IC leptin, whereas COX-2 mRNA levels were 3-fold greater in colon mucosa (Fig. 2A). Interestingly, COX-2 induction by luminal leptin paralleled a substantial and dose-dependent production of mucosa PGE2, with a 2.8-fold greater production (P<0.05 vs vehicle) being observed with 3 nM leptin (Fig. 2B). The calculated EC50 from the dose-response curve was 0.89 nM. These data indicate that intracolonic leptin induces rapid activation of STAT-3 and ERK proteins; this activation is accompanied by the induction of COX-2 expression and increased production of PGE2 in the colonic mucosa.

Histological analysis of colon mucosa sections from rats treated either with intracolonic PBS- or leptin (3 nM) after 3 hours showed no change in the architecture of the colonic mucosa (Fig. 3). However, despite no obvious changes in the number of goblet cells, 3 hours after intracolonic leptin treatment, an increase in mucus materials was detected in the crypt lumen and in the colon lumen in accordance with our previous demonstration [21].

Table 1. Sequences of Custom Primers for Real-Time Quantitative PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPAR-α</td>
<td>CCTCTTCCCCAAAGCTCCTTCA</td>
<td>GTACGAGCTGCGCATGCTC</td>
</tr>
<tr>
<td>PPAR-γ</td>
<td>TCATGACCAGGGAGTTCCCTCA</td>
<td>TCACTAAATCCAGTGATGAACTTT</td>
</tr>
<tr>
<td>TNF-α</td>
<td>CATCCTTCAAAATTCGAGTGACAA</td>
<td>TGCGATAGCAGCATGACACCC</td>
</tr>
<tr>
<td>IL-1β</td>
<td>CAACAAAAATGCTCGTG</td>
<td>TGCTGATGATCCAGTGGG</td>
</tr>
<tr>
<td>CINC (IL8)</td>
<td>GACTGTGTTGGCCCGTGGAG</td>
<td>CGCGTCAAGCTGAGTTCT</td>
</tr>
<tr>
<td>COX-2</td>
<td>GCAAATCCTGGCTGGTTCCAATC</td>
<td>GGAGAAAGCTTCCAGCTTGG</td>
</tr>
<tr>
<td>HPRT</td>
<td>GCTCGAGATGTGATCGAAGGAGA</td>
<td>TCAGCGCTTTATGTAATCCAG</td>
</tr>
</tbody>
</table>

Fig. (1). Leptin in the luminal content of rat colon, and the phosphorylation of STAT3, and ERK proteins. (A) In fluids collected from the colons of rats fed ad libitum and 24 hour-fasted, leptin-immunoreactive (IR) protein was detected, each column representing mean ± SEM. (B) Vehicle (Control) or leptin was directly delivered into the colon lumen of 24 hour-fasted rats. The rats were killed 30 min, 60 min and 5 hours after injection, the distal colon was removed, and the mucosa was scraped and divided in two fractions, rapidly frozen until use. Proteins extracts were analysed by western blot with antibodies specific for either phosphorylated STAT3, total STAT-3, phosphorylated p42 MAPK, total ERK and SOCS-3 protein; β-actin was used as a protein loading control.
The chronic effects of intracolonic leptin were further analysed in this rat model of colitis in –

**Histology of colonic sections was performed in DSS-treated rats receiving IP leptin or IC leptin (Fig. 5). In normal colonic mucosa, the crypts were straight with their base resting on the muscular mucosa (Fig. 5a). Colons from DSS-treated rats showed the infiltration of inflammatory cells, submucosal oedema, and areas of epithelial erosion with early regenerative changes (Fig. 5c). The histological changes in DSS-treated rats receiving IC leptin (Fig. 5d) were not significantly different from those observed in DSS rats treated with vehicle. We observed a more severe disruption of the colonic epithelium in colonic sections of DSS rats receiving IP leptin (not shown): a loss of entire crypts, ulceration and small area of re-epithelisation in comparison with the colonic mucosa of control DSS-treated rats. Overall, the total histological score of DSS rats receiving vehicle was further enhanced in DSS rats receiving IP leptin and was slightly but significantly lower in DSS rats receiving IC leptin (Fig. 5e). These data prompted us to analyse the mucosal expression of cytokines as another indication of the degree of intestinal inflammation after administering IC leptin.

**Inflammation-related genes in DSS-rats treated with IC leptin.** There were significant changes in the distal colon of DSS-treated rats, i.e. severe disruption of the epithelium with ulceration; thus, we used segments of proximal and transverse colon for real-time PCR analysis. Intracolonic vehicle-DSS-treated rats exhibited a slight but non significant increase in mucosal TNF-α mRNA, a 4-fold increase in mucosal IL-1β mRNA and a significant 35-fold increase in mucosal IL-8 mRNA levels (Fig. 6). DSS-induced expression of mucosal IL-1β and IL-8 was strongly decreased by 6 nM IC leptin. Note that large doses of IC leptin did not significantly affect basal mucosa TNF-α and IL-1β mRNA levels but induced a 1.5-fold increase in the levels IL-8 mRNA.

**Intracolonic leptin treatment restores PPARα and enhances PPARγ expression in DSS-treated rats.** We extended the analysis of mucosal cytokines to the expression of PPARα and PPARγ. IC leptin did not significantly affect levels of mucosal PPARα and PPARγ mRNA (Fig. 7).
PPARα mRNA levels in control DSS-treated rats were significantly lower than those in control rats (-45%; *P* < 0.05 vs control), whereas PPARγ mRNA levels did not change. Treatment of DSS-treated rats with IC leptin restored mucosal PPARα mRNA levels and enhanced the levels of PPARγ mRNA two-fold.

**DISCUSSION**

In this study, we demonstrated for the first time that leptin acting from the lumen of the colon rapidly stimulates phosphorylation of STAT-3 and p44 mitogen-activated protein kinase MAPK, two intracellular events essential for leptin action. These data are consistent with those showing that leptin activates STAT-3 in the stomach [29], and activates MAPK in the duodenum [23, 30] and in other biological systems if acting in an endocrine manner [31]. Intracolonic leptin activation of these signalling pathways was followed by increased SOCS-3 protein production, which has been reported to function as a negative regulator of leptin-receptor signalling by interfering with STAT-3 [32, 33]. Our data also demonstrate this regulatory effect. Interestingly, the concentrations of leptin inducing activation of STAT3 and MAPK in this study were compatible with those necessary for the activation of leptin receptors and with the concentrations of leptin detected in the colon luminal content [present study & 21, 22]. These results along with the expression of leptin receptors on the apical side of the colonocytes [34, 35] support the idea that these receptors are primary targets for leptin in colon juice [21, 22, 36]. This seems likely as the activation of STAT3 and MAPK was followed by induction of COX-2 and enhanced production of mucosal PGE2. Interestingly, *in vitro* studies previously reported JAK2-dependent activation of COX-2 and PGE2 production in oesophageal [37, 38] and macrophage J774.1 cells [39, 40]. Moreover, in the rat brain, leptin can induce COX-2 expression *via* an interaction with interleukin-1 beta [41]. Thus, we suggested that apical activation of leptin receptors on colonic epithelial cells may be an important factor in driving mucosal COX-2 expression, probably through STAT3- and MAPK-dependent pathways.

COX-2 is an important rate-limiting enzyme involved in the production of prostaglandins from arachidonate. Unlike COX-1, the constitutive “housekeeping” isof orm, COX-2, is an inducible isof orm of which expression occurs in most cells in response to tissue injury and can be up-regulated by growth factors and various cytokines [42]. COX-2 mRNA and protein production are up-regulated at the ulcer margin in relation to enhanced epithelial cell proliferation and increased expression of growth factors. By contrast, we have previously reported that colon leptin activates mucus secretion [21, 22], an effect consistent with our current findings. Taking into account the leading role of COX-2 and the mucus layer in the maintenance of mucosal integrity, we suggested that the apical effects of leptin on colon epithelial cells contribute to repairing tissue damage and/or attenuating colonic inflammation. This is supported by data demonstrating that deletion of the gene encoding PGE receptor EP4 subtype is associated with an increased susceptibility of the mice to DSS colitis [43]. These data along with the reported increased levels of leptin in colonic juice in IBD [22] highlight the physiological relevance of these findings in controlling intestinal inflammation.

There is convergent data arguing for a pro-inflammatory function to circulating leptin. This function, however, contrasts with the lower reported circulating leptin levels in IBD patients [44], but appears be consistent with the reported over-expression of leptin and its receptors in mesenteric adipose tissue of IBD patients [45]. Moreover, this over-expression of leptin was demonstrated in gastric mucosa colonised with *Helicobacter pylori* [19, 20] and in the colon of IBD patients with increased leptin levels in their luminal contents [22 and, unpublished results]. It is therefore possible, that in the inflamed tissue, the expression of leptin is
dependent on the severity and the timeline of the inflammatory processes. This is the case for skin tissue [46], and gastrointestinal mucosa [17, 19, 20, 22], which has been suggested to represent sources of leptin potentially secreted in the lumen during inflammation. Whether overexpression of leptin is the driving force underlying inflammatory responses or simply represent a marker of an inflammatory state is largely unknown. In one interesting study, it has been demonstrated in mice that 48 hours after the intrarectal injection of leptin the colonic epithelial wall was significantly damaged with epithelial exfoliation, indicating a pro-inflammatory function [22]. However, identifying the exact relationship between leptin acting apically of colon epithelial cells and intestinal inflammatory processes requires further study. Although leptin activates the nuclear transcription factor NF-κB [22, 47], implicated in IBD [48], this does not preclude a protective role for leptin. Indeed, data obtained from specific ablation of IKK-β in intestinal epithelial cells suggests that the primary function of NF-κB activation in IEC in response to injury is to protect the inflamed mucosa [49]. Intestinal inflammation alters patterns of proliferation and differentiation, and leptin exerts proliferative effects [37, 47, 50, 51]; thus, we can still question the beneficial effects of leptin acting locally in intestinal inflammation.

This data prompted us to analyse the role of gut leptin on DSS-induced colonic inflammation. This model is a well-characterised model with predictable disease progression. However, it also has several clinical, biochemical and hist-
tological features that closely resemble UC in humans [52, 53]. The major finding of this study was that leptin acting luminally of mucosa attenuates the severity of DSS-induced colitis, whereas treatment with peripheral leptin does not. The analysis of inflammation-related genes revealed an unexpected feature for topically supplemented leptin. With the exception of mucosal TNFα mRNA levels, DSS-induction of pro-inflammatory IL-8 and IL-1β mediators was prevented by luminal leptin. It is noteworthy that challenge of the colon lumen by leptin is not altered by its own colonic epithelial wall and the expression of TNFα and IL-1β. Collectively, these data suggest that leptin acting at apical side of colon epithelial cells is unlikely to function as a pro-inflammatory cytokine. They rather suggest that upon injury of the mucosa, leptin is likely to antagonise pro-inflammatory pathways to reduce the severity of colitis. This is supported by findings demonstrating that topically supplemented leptin improved re-epithelialisation of wounds in leptin deficient ob/ob mice [46].

Peroxisome-proliferator activated receptor-α and γ (PPAR-α,γ) are nuclear receptors reported as regulators of several genes involved in metabolic control [54]. Several studies have reported that the activation of PPARγ by specific ligands attenuates the severity and/or delays the onset of colitis in experimental mouse models of IBD [55-58]. Moreover, mice with specific deletion of PPAR-γ throughout the intestinal epithelium exhibited a great susceptibility to DSS-induced colitis arguing for a direct role of PPARγ in the colon mucosa [59]. We analysed the mechanisms further and found that intracolonic leptin completely restores the reduced levels of mucosa PPARα in DSS-induced colitis in rats, and potently enhances levels of mucosa PPARγ. Therefore, this increase in PPAR-γ mRNA probably contributes to reducing the severity of DSS colitis in rats, yet this remains to be clearly demonstrated.

In summary, our findings support the idea that leptin operating through its apical receptors coupled with the

Fig. (5). Histological changes in the colon mucosa of control and DSS rats treated with intraperitoneal or intracolonic leptin. Haematoxylin–eosin staining was performed on colon sections prepared from paraffin embedded samples fixed in Bouin solution and processed as described in Material & Methods. Shown are representative photomicrographs of H&E-stained paraffin sections of distal colon from control (a), IC leptin treated (b), DSS alone (c) and IC leptin-DSS treated (d). Histological scores of disease severity (e). Each column represents the mean ± SEM of at least 15 rats. ***P < 0.001 vs control (vehicle).

Fig. (6). Chronic intracolonic leptin on inflammation-related genes in DSS colitis rats. Total RNA was extracted from a segment from the proximal and middle colon in control (drinking water) and DSS rats receiving intracolonic PBS or 6 nM leptin; these samples were analysed by quantitative RT-PCR, as described in the Materials and Methods section. Quantification of mRNA encoding TNF-α (upper panel), IL-1β (middle panel), and IL-8 (lower panel) normalised to mRNA for HPRT. NS: non significant; * P<0.05; ** P<0.01; *** P<0.001 vs Control.
Fig. (7). Intracolonic leptin prevents reduction of PPARγ and induces PPARα in colon mucosa in DSS rats. Total RNA was extracted from the middle colon in control and DSS rats receiving intracolonic vehicle or leptin, and was analysed by quantitative RT-PCR, as described in the Material and Methods section. Quantification of mRNA encoding PPARα and PPARγ normalised to mRNA for HPRT. One-way ANOVA with Tukey-Kramer multiple comparison post-test. NS: non significant; * P<0.05 ; ** P<0.01 vs control.


El Homsi M, Ducroc R, Claudre J, et al. Leptin modulates the expression of secreted and membrane-associated mucins in colonic...

[37] Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OEE3 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007; 274: 60-68.


